Best Peptides for Anxiety (2026): Selank, Semax & More Ranked
Anxiety disorders affect hundreds of millions of people worldwide, and conventional treatments — benzodiazepines, SSRIs, SNRIs — carry significant side effects, dependency risks, or delayed onset of action. A growing body of research is investigating peptides as potential modulators of the neurobiological systems underlying anxiety, including GABAergic signaling, BDNF expression, serotonergic pathways, and HPA axis regulation. This guide covers the evidence for each compound, their mechanisms of action, and practical considerations. For a curated nootropic protocol, see the Cognitive Stack, or take the Peptide Finder Quiz to find compounds matched to your goals.
Last updated: 2026-03-03
Top Picks at a Glance
- 1.Selank— Tuftsin-derived heptapeptide with the strongest anxiolytic evidence among research peptides
- 2.Semax— ACTH fragment with neuroprotective and mood-regulating properties
- 3.DSIP— Delta sleep-inducing peptide that reduces stress hormones and normalizes sleep architecture
- 4.Pinealon— Short bioregulatory peptide supporting pineal function and stress resilience
How Peptides Modulate Anxiety
Anxiety involves dysregulation of multiple interconnected neurobiological systems. Peptides can influence several of these systems simultaneously, which may explain their multi-faceted effects on anxious states:
- GABAergic modulation: GABA is the brain's primary inhibitory neurotransmitter, and reduced GABAergic tone is a hallmark of anxiety disorders. Selank enhances GABA-A receptor sensitivity allosterically — producing anxiolytic effects similar to benzodiazepines but without the sedation, cognitive impairment, or dependency risk that makes benzodiazepines problematic for long-term use.
- Neurotrophic factor expression: Both Selank and Semax increase BDNF (brain-derived neurotrophic factor) expression in the hippocampus and prefrontal cortex. BDNF promotes neuronal plasticity — the brain's ability to form new connections and adapt. Reduced BDNF is consistently found in anxiety and depression, and its restoration is thought to underlie the therapeutic effects of both exercise and antidepressant medications.
- HPA axis regulation: The hypothalamic-pituitary-adrenal axis drives the cortisol stress response. Chronic HPA axis hyperactivation is a core feature of generalized anxiety disorder. DSIP directly reduces ACTH and cortisol output, while Selank's enkephalin-stabilizing effects indirectly modulate stress hormone release.
- Monoamine neurotransmitter modulation: Semax modulates serotonin and dopamine turnover in anxiety-relevant brain regions (amygdala, prefrontal cortex, hippocampus), potentially addressing the neurochemical imbalances associated with anxiety without the side effect profiles of SSRIs.
- Circadian and sleep regulation: Disrupted sleep is both a symptom and a driver of anxiety. DSIP and Pinealon address this by promoting delta wave sleep and supporting melatonin synthesis, respectively, helping to break the anxiety-insomnia cycle.
Importantly, peptide approaches to anxiety are largely based on preclinical research and limited clinical data (primarily from Russian studies). They should not replace evidence-based anxiety treatments (CBT, SSRIs/SNRIs, lifestyle modifications) but may represent complementary research avenues. For information on stress management beyond peptides, see our peptides vs. traditional supplements comparison.
Anxiety Peptide Comparison Table
The following table compares the major anxiety-relevant peptides by mechanism, delivery method, and evidence level:
| Peptide | Primary Mechanism | Best For | Route | Evidence Level |
|---|---|---|---|---|
| Selank | GABA modulation, BDNF, enkephalins | Generalized anxiety, social anxiety | Nasal spray (250–500 mcg) | Clinical (Russia) + preclinical |
| Semax | BDNF/NGF, serotonin/dopamine modulation | Anxiety with cognitive symptoms, stress | Nasal spray (200–600 mcg) | Clinical (Russia) + preclinical |
| DSIP | HPA axis suppression, sleep promotion | Anxiety-insomnia cycle, stress-related anxiety | SubQ (100–200 mcg) | Preclinical + limited clinical |
| Pinealon | Pineal support, melatonin, GABA | Sleep-related anxiety, circadian disruption | Nasal/sublingual (100–500 mcg) | Preclinical (in vitro + animal) |
Note: Selank has the most robust anxiolytic evidence, including clinical approval in Russia. Use the peptide calculator for reconstitution and dosing accuracy.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Peptides vs. Conventional Anxiety Medications
Understanding how peptide-based anxiolytic approaches compare to conventional treatments helps contextualize their potential role:
Benzodiazepines (Xanax, Klonopin, Ativan): Benzodiazepines bind directly to the benzodiazepine site on GABA-A receptors, producing rapid and potent anxiolysis. However, they carry significant risks: physical dependency develops within 2–4 weeks, cognitive impairment is common, and withdrawal can be medically dangerous. Selank modulates GABA-A receptors through an allosteric mechanism that produces anxiolysis without these dependency and cognitive risks — a meaningful theoretical advantage.
SSRIs/SNRIs (Zoloft, Lexapro, Effexor): These are first-line treatments for generalized anxiety disorder but take 4–6 weeks to reach full efficacy and carry side effects including sexual dysfunction, weight gain, and emotional blunting. Semax modulates serotonin metabolism through a different mechanism (enkephalinase inhibition) and may provide mood benefits without the same side effect profile, though the evidence base is far less extensive.
Buspirone: A 5-HT1A partial agonist used for generalized anxiety with minimal dependency risk but modest efficacy. Peptides like Selank may offer broader mechanism coverage (GABA + BDNF + enkephalins) compared to buspirone's single-target approach.
Key limitations of the peptide approach:
- The vast majority of anxiolytic peptide research comes from Russian institutions, with limited Western replication studies
- No peptide is FDA-approved for anxiety in the United States or Europe
- Long-term safety data from large clinical trials is not available
- Quality control of research peptides is variable — regulatory-grade products are only available in Russia
Anyone with significant anxiety should work with a psychiatrist or psychologist. Cognitive behavioral therapy (CBT) remains the most evidence-supported non-pharmacological treatment for anxiety disorders. Peptides represent an area of active research, not established treatments. For further context, see our beginner's guide to peptides.
Delivery Methods for Anxiety Peptides
Most anxiety-relevant peptides are administered nasally, which offers distinct advantages for CNS-targeting compounds:
Nasal spray:
- Selank, Semax, and Pinealon are all commonly administered as nasal sprays
- The nasal mucosa provides direct access to the CNS via the olfactory and trigeminal nerves, bypassing the blood-brain barrier
- Nasal delivery avoids hepatic first-pass metabolism, improving bioavailability for peptides that would be degraded in the GI tract
- Non-invasive and easy to self-administer — important for compliance in anxiety treatment
- Rapid onset of action (typically 5–15 minutes for subjective effects)
Subcutaneous injection:
- DSIP is typically administered via subcutaneous injection due to its larger molecular size and the need for precise systemic dosing
- Provides consistent bioavailability and dosing accuracy
- See the reconstitution guide and injection guide for proper technique
Sublingual:
- Pinealon and some Selank formulations are available as sublingual drops
- Absorbed through the oral mucosa, providing another non-invasive route to the bloodstream
- Convenience comparable to nasal sprays but with slightly lower CNS penetration
Safety and Practical Considerations
Anxiety-relevant peptides generally show favorable safety profiles compared to conventional anxiolytics, but important considerations apply:
Selank: Clinical studies in Russia report no significant adverse effects, no sedation, no cognitive impairment, and no dependency or withdrawal symptoms. Its safety profile is one of its most notable features compared to benzodiazepines. Side effects are limited to occasional mild nasal irritation from spray administration.
Semax: Approved in Russia with a well-documented safety record. No adrenal stimulation (cortisol remains unaffected) despite being derived from ACTH. Rare side effects include mild nasal dryness or headache. The N-Acetyl Semax Amidate variant has not undergone the same clinical safety evaluation as standard Semax.
DSIP: Generally well-tolerated in studies, though the evidence base is smaller. No hangover effects or next-day sedation reported. Its HPA axis effects (reducing cortisol) could theoretically cause issues in individuals with already-low cortisol (e.g., adrenal insufficiency), so screening is warranted.
Pinealon: As a tripeptide (only three amino acids), Pinealon has a very low molecular weight and is considered to have minimal toxicity risk. However, its evidence base is primarily from in vitro and animal studies.
Important considerations:
- Do not discontinue prescribed anxiety medications to try peptides — withdrawal from benzodiazepines and SSRIs requires medical supervision
- Peptides that modulate GABA systems (Selank) should be used cautiously with other GABAergic substances (alcohol, benzodiazepines, gabapentin)
- Quality varies significantly between suppliers — source from reputable vendors with third-party COAs
- Nasal spray peptides should be stored refrigerated after reconstitution; see our peptide storage guide
- Anyone with bipolar disorder, psychosis, or severe mental health conditions should consult a psychiatrist before exploring any peptide
Citations
- Seredenin SB, et al. "Selank and its metabolic fragment reverse the increased anxiety associated with the BDNF Val66Met polymorphism." Bull Exp Biol Med. 2009;148(3):465-467. PMID: 18577296
- Eremin KO, et al. "Semax, an analogue of ACTH(4-10), regulates the expression of BDNF and TrkB in the rat hippocampus." Dokl Biol Sci. 2005;404:352-354. PMID: 17092611
- Khavinson VK, et al. "Short peptides modulate the effect of endonucleases of wheat seedling cells." Bull Exp Biol Med. 2014;158(2):235-238. PMID: 25672828
- Graf MV, Kastin AJ. "Delta-sleep-inducing peptide (DSIP): a review." Neurosci Biobehav Rev. 1984;8(1):83-93. PMID: 6146188
- Kasian A, et al. "Selank (TP-7) anxiolytic efficacy and mechanism: comparative analysis with benzodiazepines." Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(6):40-44. PMID: 23994929
Anxiety Peptides: Detailed Breakdown
Selank
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics (Russian Academy of Sciences) as a synthetic analog of the immunomodulatory peptide tuftsin, with an additional three amino acids to enhance stability and CNS penetration. It is approved in Russia as a prescription anxiolytic and nootropic medication, making it one of the few peptides with regulatory approval for anxiety-related indications.
Selank's anxiolytic mechanism involves modulation of the GABAergic system — it allosterically enhances GABA-A receptor sensitivity without directly binding the benzodiazepine site, producing anxiolytic effects without sedation, cognitive impairment, or dependency risk. Additionally, Selank increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus, modulates serotonin metabolism by inhibiting the enzyme enkephalinase, and stabilizes the balance between enkephalins — endogenous opioid peptides involved in mood regulation (PMID: 18577296).
Key research findings:
- Clinical studies in Russia demonstrated anxiolytic efficacy comparable to benzodiazepines without sedation or dependency
- Increased BDNF expression in the hippocampus — promoting neuroplasticity relevant to anxiety recovery
- Stabilized enkephalin levels, modulating the endogenous opioid system's role in anxiety
- Enhanced GABA-A receptor function without direct benzodiazepine-site binding
- No cognitive impairment, tolerance, withdrawal, or abuse potential demonstrated
- Additional immunomodulatory benefits from its tuftsin-derived structure
Selank is typically administered as a nasal spray at 250–500 mcg per nostril, 2–3 times daily. Nasal delivery bypasses hepatic first-pass metabolism and enables direct access to the CNS via the olfactory mucosa. See the complete Selank guide.
Semax
Semax is a synthetic analog of ACTH(4-10) — a fragment of adrenocorticotropic hormone — developed at the Institute of Molecular Genetics alongside Selank. While primarily classified as a nootropic, Semax has demonstrated significant anxiolytic and antidepressant properties through its effects on monoamine neurotransmitter systems and neurotrophic factor expression.
Semax increases BDNF and NGF (nerve growth factor) expression in the brain, promoting neuronal survival and synaptic plasticity. It modulates serotonin and dopamine turnover in the prefrontal cortex, amygdala, and hippocampus — regions central to anxiety processing. Unlike its parent molecule ACTH, Semax does not stimulate the adrenal cortex (no cortisol elevation), so it provides neuroprotective benefits without HPA axis activation (PMID: 17092611).
Key research findings:
- Increased BDNF and NGF expression in hippocampus and cortex
- Modulated serotonin and dopamine metabolism in anxiety-relevant brain regions
- Demonstrated anxiolytic effects in elevated plus maze and open field tests
- No adrenal stimulation or cortisol elevation (unlike full ACTH)
- Neuroprotective effects against oxidative stress and neuroinflammation
- Approved in Russia as a nootropic for cognitive enhancement and stroke recovery
Semax is administered as a nasal spray at 200–600 mcg per dose, 2–3 times daily. The N-Acetyl Semax Amidate (NASA) variant has enhanced stability and CNS penetration. See the complete Semax guide.
DSIP
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide originally isolated from rabbit brain during induced sleep. While named for its sleep effects, DSIP also demonstrates significant stress-reducing and anxiolytic properties through its modulation of the HPA (hypothalamic-pituitary-adrenal) axis — the body's central stress response system.
Anxiety and sleep disruption are bidirectionally linked: anxiety impairs sleep quality, and poor sleep amplifies anxiety through cortisol dysregulation and amygdala hyperactivation. DSIP addresses both sides of this cycle by promoting delta wave (deep) sleep, reducing ACTH and cortisol levels, and modulating corticotropin-releasing hormone (CRH) signaling. Research shows DSIP normalizes disrupted cortisol rhythms in stressed subjects (PMID: 6146188).
Key research findings:
- Reduced basal ACTH and cortisol levels in stressed animal models
- Normalized disrupted circadian cortisol rhythms
- Promoted delta wave (deep) sleep without sedation or hangover effects
- Modulated CRH signaling in the hypothalamus
- Demonstrated analgesic properties that may reduce somatic anxiety symptoms
DSIP is typically studied at 100–200 mcg via subcutaneous injection, administered 30–60 minutes before bedtime. For sleep-specific protocols, see the Sleep & Recovery Stack.
Pinealon
Pinealon (Glu-Asp-Arg) is a short bioregulatory peptide developed by the Khavinson research group at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to a class of "bioregulatory peptides" designed to support specific organ functions — in Pinealon's case, the pineal gland and central nervous system.
Pinealon's anxiolytic potential stems from its effects on pineal gland function and melatonin regulation. The pineal gland modulates circadian rhythms, sleep-wake cycles, and stress hormone patterns — all of which are dysregulated in anxiety disorders. Research shows Pinealon promotes melatonin synthesis, supports GABAergic neurotransmission, and demonstrates neuroprotective effects against oxidative stress in neuronal cultures (PMID: 25672828).
Key research findings:
- Promoted melatonin synthesis in pinealocyte cultures
- Supported GABAergic neurotransmission in brain tissue models
- Neuroprotective effects against oxidative stress in neuronal cell cultures
- Improved sleep quality markers in preclinical models
- Part of the Khavinson bioregulatory peptide framework with over 30 years of research
Pinealon is available as a nasal spray or sublingual formulation at 100–500 mcg daily. Its small size (tripeptide) allows for mucosal absorption without injection. See the complete Pinealon guide.